The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
Open accessAbstract
BACKGROUND: Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in TAM resistance. However, the regulation of HOXB13 in TAM-resistant breast cancer remains largely unexplored. Here, we were interested in the potential effect of HBXIP, an oncoprotein involved in the acceleration of cancer progression, on the modulation of HOXB13 in TAM resistance of breast cancer. METHODS: The Kaplan-Meier plotter cancer database and GEO dataset were used to analyze the association between HBXIP expression and relapse-free survival. The correlation of HBXIP and HOXB13 in ER+ breast cancer was assessed by human tissue microarray. Immunoblotting analysis, qRT-PCR assay, immunofluorescence staining, Co-IP assay, ChIP assay, luciferase reporter gene assay, cell viability assay, and colony formation assay were performed to explore the possible molecular mechanism by which HBXIP modulates HOXB13. Cell viability assay, xenograft assay, and immunohistochemistry staining analysis were utilized to evaluate the effect of the HBXIP/HOXB13 axis on the facilitation of TAM resistance in vitro and in vivo. RESULTS: The analysis of the Kaplan-Meier plotter and the GEO dataset showed that mono-TAM-treated breast cancer patients with higher HBXIP expression levels had shorter relapse-free survivals than patients with lower HBXIP expression levels. Overexpression of HBXIP induced TAM resistance in ER+ breast cancer cells. The tissue microarray analysis revealed a positive association between the expression levels of HBXIP and HOXB13 in ER+ breast cancer patients. HBXIP elevated HOXB13 protein level in breast cancer cells. Mechanistically, HBXIP prevented chaperone-mediated autophagy (CMA)-dependent degradation of HOXB13 via enhancement of HOXB13 acetylation at the lysine 277 residue, causing the accumulation of HOXB13. Moreover, HBXIP was able to act as a co-activator of HOXB13 to stimulate interleukin (IL)-6 transcription in the promotion of TAM resistance. Interestingly, aspirin (ASA) suppressed the HBXIP/HOXB13 axis by decreasing HBXIP expression, overcoming TAM resistance in vitro and in vivo. CONCLUSIONS: Our study highlights that HBXIP enhances HOXB13 acetylation to prevent HOXB13 degradation and co-activates HOXB13 in the promotion of TAM resistance of breast cancer. Therapeutically, ASA can serve as a potential candidate for reversing TAM resistance by inhibiting HBXIP expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, there is increasing evidence that cancer cells could use acetylation as an adaptation to confer drug resistance [109,110], proving non-histone acetylation as both a precise and crucial function to tumor processes.”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Autophagy fights disease through cellular self-digestion
Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Autophagy: molecular machinery for self-eating
Yorimitsu, T., & Klionsky, D. J. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401765 · Cited by 1,535
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Ragulator Is a GEF for the Rag GTPases that Signal Amino Acid Levels to mTORC1
Bar-Peled, L., Schweitzer, L. D., Zoncu, R., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.07.032 · Cited by 918 · cited 2×
“Bar-Peled’s group has discovered that HBXIP functions as a regulatory component in the amino acid-induced activation of mTORC1 [16].”
Background
Cited by
Wang, T., Fu, X., Jin, T., Zhang, L., Liu, B., Wu, Y., Xu, F., Wang, X., Ye, K., Zhang, W., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.048 · Cited by 135
Self-citationLiu, Y., Zhou, Z., Hou, J.-T., Xiong, W., Kim, H., Chen, J., Zheng, C., Jiang, X., Yoon, J., & Shen, J. (2022) · Advanced Materials · doi:10.1002/adma.202206121 · Cited by 129
Zhang, L., Wan, Y., Zhang, Z., Jiang, Y., Lang, J., Cheng, W., & Zhu, L. (2020) · RNA Biology · doi:10.1080/15476286.2020.1841458 · Cited by 119
Self-citationHomeobox Genes in Cancers: From Carcinogenesis to Recent Therapeutic Intervention
Feng, Y., Zhang, T., Wang, Y., Xie, M., Ji, X., Luo, X., Huang, W., & Xia, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770428 · Cited by 97
Yu, M., Zhan, J., & Zhang, H. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109469 · Cited by 71
Metadata
- Authors
- Liu, B., Wang, T., Wang, H., Zhang, L., Xu, F., Fang, R., Li, L., Cai, X., Wu, Y., Zhang, W., & Ye, L.
- Affiliations
- Nankai University (CN)
- Corresponding author
- Zhang, Weiying
- Ye, Lihong
- ORCID
- Venue
- Journal of Hematology & Oncology
- Published
- 2018-02-23
- Volume
- 11
- Issue
- 1
- Pages
- 26-26
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC5824486
- OpenAlex
- W2796139531
- Cited by
- 73
- References
- 72
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 5 · 2020: 10 · 2019: 7
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Basic Research Program of China (2015CB553905)
- National Natural Scientific Foundation of China (81372186, 31670771)
- Fundamental Research Funds for the Central Universities
- Project of Prevention and Control of Key Chronic Non Infectious Diseases (2016YFC1303401)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- HOXB13, tamoxifen resistance, estrogen receptor-positive breast cancer, protein acetylation, chaperone-mediated autophagy, protein degradation, transcriptional coactivation, interleukin-6, aspirin, relapse-free survival, oncoprotein, drug resistance mechanisms, drug target identification
- MeSH terms
- Acetylation, Animals, Breast Neoplasms, Female, Humans, Mice, Inbred BALB C, Tamoxifen, Homeodomain Proteins, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Adaptor Proteins, Signal Transducing, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. https://app.cochat.ai/papers/10.1186/s13045-018-0577-5
- The paper
- Liu, B., Wang, T., Wang, H., Zhang, L., Xu, F., Fang, R., Li, L., Cai, X., Wu, Y., Zhang, W., & Ye, L. (2018). Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-018-0577-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.